Ideaya Biosciences Financials
This page shows Ideaya Biosciences (IDYA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ideaya Biosciences has an operating margin of -72.8%, meaning the company retains $-73 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -4671.1% the prior year.
Ideaya Biosciences's revenue surged 3024.4% year-over-year to $218.7M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Ideaya Biosciences carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 11.34, Ideaya Biosciences holds $11.34 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Ideaya Biosciences generated -$71.1M in operating cash flow, capex of $2.4M consumed most of it, leaving -$73.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Ideaya Biosciences's ROE of 11.1% shows moderate profitability relative to equity, earning a score of 44/100.
Ideaya Biosciences passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Ideaya Biosciences generates $0.63 in operating cash flow (-$71.1M OCF vs -$113.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Ideaya Biosciences generated $218.7M in revenue in fiscal year 2025. This represents an increase of 3024.4% from the prior year.
Ideaya Biosciences's EBITDA was -$156.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.8% from the prior year.
Ideaya Biosciences generated -$73.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.8% from the prior year.
Ideaya Biosciences reported -$113.7M in net income in fiscal year 2025. This represents an increase of 58.6% from the prior year.
Ideaya Biosciences earned $-1.28 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.9% from the prior year.
Ideaya Biosciences held $112.8M in cash against $0 in long-term debt as of fiscal year 2025.
Ideaya Biosciences had 88M shares outstanding in fiscal year 2025. This represents an increase of 0.3% from the prior year.
Ideaya Biosciences's operating margin was -72.8% in fiscal year 2025, reflecting core business profitability. This is up 4598.2 percentage points from the prior year.
Ideaya Biosciences's net profit margin was -52.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3869.1 percentage points from the prior year.
Ideaya Biosciences's ROE was 11.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Ideaya Biosciences invested $314.7M in research and development in fiscal year 2025. This represents an increase of 6.8% from the prior year.
Ideaya Biosciences invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 38.6% from the prior year.
IDYA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $207.8M | N/A | N/A | $7.0M | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $83.0M+11.8% | $74.2M+4.7% | $70.9M-49.4% | $140.2M+145.3% | $57.2M+4.8% | $54.5M+27.4% | $42.8M |
| SG&A Expenses | N/A | $16.4M+12.4% | $14.6M+8.0% | $13.5M+23.3% | $11.0M+12.5% | $9.7M-6.3% | $10.4M+26.6% | $8.2M |
| Operating Income | N/A | $108.5M+222.1% | -$88.8M-5.2% | -$84.4M+41.5% | -$144.1M-115.5% | -$66.9M-3.0% | -$64.9M-27.3% | -$51.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | $119.2M+253.9% | -$77.5M-7.4% | -$72.2M+44.6% | -$130.3M-151.5% | -$51.8M+1.8% | -$52.8M-33.4% | -$39.6M |
| EPS (Diluted) | N/A | $1.33+251.1% | $-0.88-7.3% | $-0.82+47.1% | $-1.55-158.3% | $-0.60+11.8% | $-0.68-28.3% | $-0.53 |
IDYA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B-6.4% | $1.2B+13.8% | $1.0B-5.4% | $1.1B-2.1% | $1.1B-9.3% | $1.2B+27.3% | $973.7M+1.3% | $961.5M |
| Current Assets | $666.7M-16.9% | $802.7M+17.1% | $685.6M-3.1% | $707.9M+2.6% | $689.7M-26.0% | $932.2M+30.7% | $713.2M+0.5% | $709.4M |
| Cash & Equivalents | $112.8M-62.3% | $298.9M+160.7% | $114.6M-11.8% | $130.0M+54.1% | $84.4M-78.9% | $400.3M+118.7% | $183.0M+69.0% | $108.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $86.4M-7.2% | $93.1M+14.1% | $81.6M+6.7% | $76.5M+17.8% | $64.9M+9.2% | $59.5M+41.5% | $42.0M+60.2% | $26.2M |
| Current Liabilities | $58.8M-8.8% | $64.5M+16.6% | $55.3M+8.8% | $50.8M+10.4% | $46.1M+13.3% | $40.7M-0.2% | $40.7M+63.2% | $25.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.0B-6.3% | $1.1B+13.8% | $959.7M-6.3% | $1.0B-3.3% | $1.1B-10.3% | $1.2B+26.7% | $931.7M-0.4% | $935.3M |
| Retained Earnings | -$736.5M-12.7% | -$653.3M+15.4% | -$772.5M-11.1% | -$695.0M-11.6% | -$622.8M-26.5% | -$492.5M-11.8% | -$440.7M-13.6% | -$387.9M |
IDYA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$90.5M-163.6% | $142.2M+327.6% | -$62.5M-3.5% | -$60.3M+50.4% | -$121.7M-147.1% | -$49.2M-49.7% | -$32.9M+24.9% | -$43.8M |
| Capital Expenditures | $333K+692.9% | $42K-93.7% | $663K-50.2% | $1.3M+20.7% | $1.1M+141.1% | $457K-53.0% | $973K-26.6% | $1.3M |
| Free Cash Flow | -$90.8M-163.9% | $142.2M+325.2% | -$63.1M-2.4% | -$61.7M+49.8% | -$122.8M-147.0% | -$49.7M-46.8% | -$33.9M+25.0% | -$45.1M |
| Investing Cash Flow | -$97.5M-333.5% | $41.8M-9.0% | $45.9M-42.5% | $79.8M+140.5% | -$197.1M-883.8% | -$20.0M-129.2% | $68.6M+119.4% | -$354.0M |
| Financing Cash Flow | $2.1M+607.6% | $301K-75.0% | $1.2M-95.4% | $26.1M+849.6% | $2.8M-99.0% | $286.5M+631.2% | $39.2M-88.8% | $349.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IDYA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | 52.2% | N/A | N/A | -2059.1%-1642.0pp | -417.1%+505.9pp | -922.9%-589.4pp | -333.5% |
| Net Margin | N/A | 57.4% | N/A | N/A | -1861.6%-1520.2pp | -341.4%+446.6pp | -788.0%-488.0pp | -300.0% |
| Return on Equity | N/A | 10.9% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | 10.1%+17.5pp | -7.4%-0.9pp | -6.6%+5.0pp | -11.6%-7.4pp | -4.2%+1.2pp | -5.4%-1.3pp | -4.1% |
| Current Ratio | 11.34-1.1 | 12.44+0.1 | 12.39-1.5 | 13.92-1.0 | 14.97-8.0 | 22.93+5.4 | 17.50-10.9 | 28.42 |
| Debt-to-Equity | 0.080.0 | 0.090.0 | 0.09+0.0 | 0.07+0.0 | 0.06+0.0 | 0.050.0 | 0.05+0.0 | 0.03 |
| FCF Margin | N/A | 68.4% | N/A | N/A | -1753.7%-1370.8pp | -382.9%+586.2pp | -969.1%-615.2pp | -353.9% |
Similar Companies
Frequently Asked Questions
What is Ideaya Biosciences's annual revenue?
Ideaya Biosciences (IDYA) reported $218.7M in total revenue for fiscal year 2025. This represents a 3024.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ideaya Biosciences's revenue growing?
Ideaya Biosciences (IDYA) revenue grew by 3024.4% year-over-year, from $7.0M to $218.7M in fiscal year 2025.
Is Ideaya Biosciences profitable?
No, Ideaya Biosciences (IDYA) reported a net income of -$113.7M in fiscal year 2025, with a net profit margin of -52.0%.
What is Ideaya Biosciences's earnings per share (EPS)?
Ideaya Biosciences (IDYA) reported diluted earnings per share of $-1.28 for fiscal year 2025. This represents a 61.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Ideaya Biosciences's EBITDA?
Ideaya Biosciences (IDYA) had EBITDA of -$156.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ideaya Biosciences's operating margin?
Ideaya Biosciences (IDYA) had an operating margin of -72.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ideaya Biosciences's net profit margin?
Ideaya Biosciences (IDYA) had a net profit margin of -52.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ideaya Biosciences's return on equity (ROE)?
Ideaya Biosciences (IDYA) has a return on equity of 11.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ideaya Biosciences's free cash flow?
Ideaya Biosciences (IDYA) generated -$73.5M in free cash flow during fiscal year 2025. This represents a 70.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ideaya Biosciences's operating cash flow?
Ideaya Biosciences (IDYA) generated -$71.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ideaya Biosciences's total assets?
Ideaya Biosciences (IDYA) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ideaya Biosciences's capital expenditures?
Ideaya Biosciences (IDYA) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ideaya Biosciences spend on research and development?
Ideaya Biosciences (IDYA) invested $314.7M in research and development during fiscal year 2025.
How many shares does Ideaya Biosciences have outstanding?
Ideaya Biosciences (IDYA) had 88M shares outstanding as of fiscal year 2025.
What is Ideaya Biosciences's current ratio?
Ideaya Biosciences (IDYA) had a current ratio of 11.34 as of fiscal year 2025, which is generally considered healthy.
What is Ideaya Biosciences's debt-to-equity ratio?
Ideaya Biosciences (IDYA) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ideaya Biosciences's return on assets (ROA)?
Ideaya Biosciences (IDYA) had a return on assets of -10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ideaya Biosciences's cash runway?
Based on fiscal year 2025 data, Ideaya Biosciences (IDYA) had $112.8M in cash against an annual operating cash burn of $71.1M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Ideaya Biosciences's Piotroski F-Score?
Ideaya Biosciences (IDYA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ideaya Biosciences's earnings high quality?
Ideaya Biosciences (IDYA) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ideaya Biosciences?
Ideaya Biosciences (IDYA) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.